Several recently published works, demonstrated that even in the absence of exogenous ligands, AHR is overexpressed and constitutively active in a variety of human and/or rodent tumors including breast cancer, lung adenocarcinoma, pancreatic and prostate cancer [12, 16, 17]. The gene discussed is AHR; the disease is prostate cancer.